Course

What Does the Future Hold in the Treatment of RA

We will explore recent systematic reviews that provide a snapshot of the current RA evidence base supporting different treatment options at each stage of disease. We will also look ahead to new therapies, including biosimilar agents, and discuss where these new treatments may fit into evolving best practices in the care of patients with RA.

0 out of 3 steps completed0%
0 Lessons

LOOKING AT THE HORIZON: What Does the Future Hold in RA Treatment?

PROVIDED BY

Support for this activity has been made possible through an educational grant from Pfizer and Lilly

TARGET AUDIENCE

This activity has been designed to meet the educational needs of nurses and nurse practitioners. Other healthcare providers may also participate.

ACTIVITY DESCRIPTION

In this issue of Rheumatology Nurse Practice, we will explore recent systematic reviews that provide a snapshot of the current RA evidence base supporting different treatment options at each stage of disease. We will also look ahead to new therapies, including biosimilar agents, and discuss where these new treatments may fit into evolving best practices in the care of patients with RA.

LEARNING OBJECTIVES

After participating in the activity, learners should be better able to:

  • Analyze primary conclusions regarding efficacy and safety of recent systematic reviews of common treatment regimens used in patients with RA
  • Assess the potential impact of the introduction of biosimilars on your clinical practice
  • Determine appropriate shingles and varicella vaccination protocols in patients being introduced to tofacitinib therapy
  • Discuss the complexities of dealing with parents of pediatric patients, especially when aggressive treatment options are being considered

DISCLOSURE STATEMENT

According to the disclosure policy of RNS, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence.

RELATIONSHIPS ARE ABBREVIATED AS FOLLOWS:

E: Educational planning committee
G: Grant/research support recipient
A: Advisor/review panel member
C: Consultant
S: Stock shareholder
SB: Speaker bureau
PE: Promotional event talks
H: Honoraria
O: Other

DISCLOSURES AS FOLLOWS:

Jacqueline Fritz, RN, MSN, CNS, RN-BC, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Lilly, AbbVie, Celgene, Horizon, Momenta Pharmaceuticals/A; Celgene, AbbVie, Genentech, Horizon/SB.

Cathy Patty-Resk, MSN, RN, CPNP-PC, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Horizon, Novartis/A

Iris Zink, MSN, NP, RN-BC, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: AbbVie, Pfizer, Crescendo/A, SB; Celgene, Sanofi/A; Antares/C; Bristol Myers-Squibb/SB.

Elizabeth Kirchner, CNP, RN-BC, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Horizon, Novartis, UCB, Lilly, GlaxoSmithKline, Boehringer Ingelheim/AB; Crescendo Biosciences/SB.

INDEPENDENT CLINICAL PEER REVIEWER

Linda Grinnell-Merrick, MS, NP.BC, University of Rochester Medical Center Rochester (NY) has disclosed the following relationships: Pfizer, GlaxoSmithKline, Horizon/A; Janssen/C, SB; AbbVie, Celgene/SB.

OFF-LABEL PRODUCT DISCLOSURE

This activity will review off-label or investigational information of the following: Sirukumab, baricitinib, clazakizumab, olokizumab, filgotinib, upadacitinib, peficitinib, decernotinib, ixekizumab, secukinumab, brodalumab, infliximab.dyyb, etanercept-szzs, adalimumab-atto, infliximab-abda, and BI 695501.

PLANNING COMMITTEE

Kim Cheramie, Lead Nurse Planner, Rheumatology Nurses Society, has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Scott Kober, MBA, President, MedCaseWriter, has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Anne Jacobson, MPH, CHCP, Medical Writer, has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Kevin D. Lyons, Executive Director of the Rheumatology Nurses Society and Chief Executive Officer of Lyons Den Solutions, LLC, has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of the activity.

ACCREDITATION AND CREDIT DESIGNATION

Nurses

Rheumatology Nurses Society is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Rheumatology Nurses Society designates this educational activity for 1.25 contact hours and 0.75 pharmacotherapeutic contact hours.

METHOD OF PARTICIPATION

There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CNE credit for your participation, please go to rnsnurse.org/rnpce, complete the post-test (achieving a passing grade of 70% or greater), and program evaluation. Your certificate can be printed immediately.

COPYRIGHT

© 2017. This CNE-certified activity is held as copyrighted © by Rheumatology Nurses Society. Through this notice, the Rheumatology Nurses Society grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).